

# Finerenone (stage 3 and 4 renal insufficiency)

Benefit assessment according to §35a SGB V<sup>1</sup>



EXTRACT

Project: A23-15

Version: 1.0

Status: 30 May 2023

---

<sup>1</sup> Translation of Sections I 1 to I 6 of the dossier assessment *Finerenon (Niereninsuffizienz, Stadium 3 und 4)* – *Nutzenbewertung gemäß § 35a SGB V*. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding.

# Publishing details

**Publisher**

Institute for Quality and Efficiency in Health Care

**Topic**

Finerenone (stage 3 and 4 renal insufficiency) – Benefit assessment according to §35a SGB V

**Commissioning agency**

Federal Joint Committee

**Commission awarded on**

24 February 2023

**Internal Project No.**

A23-15

**Address of publisher**

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen  
Im Mediapark 8  
50670 Köln  
Germany

Phone: +49 221 35685-0

Fax: +49 221 35685-1

E-mail: [berichte@iqwig.de](mailto:berichte@iqwig.de)

Internet: [www.iqwig.de](http://www.iqwig.de)

### **Medical and scientific advice**

- Jochen Schneider, Saarland University Medical Center & University of Luxembourg, Germany

IQWiG thanks the medical and scientific advisor for his contribution to the dossier assessment. However, the advisor was not involved in the actual preparation of the dossier assessment. The responsibility for the contents of the dossier assessment lies solely with IQWiG.

### **Patient and family involvement**

The questionnaire on the disease and its treatment was answered by one person.

IQWiG thanks the respondent for participating in the written exchange about how she experienced the disease and its treatment and about the treatment goals. The respondent was not involved in the actual preparation of the dossier assessment.

### **IQWiG employees involved in the dossier assessment**

- Lukas Gockel
- Simone Heß
- Stefan Kobza
- Philip Kranz
- Prateek Mishra
- Mattea Patt
- Daniela Preukschat
- Min Ripoll

### **Keywords**

Finerenone, Renal Insufficiency – Chronic, Diabetes Mellitus – Type 2, Benefit Assessment, NCT02545049, NCT02540993

## **Part I: Benefit assessment**

# I Table of contents

	<b>Page</b>
<b>I List of tables .....</b>	<b>I.3</b>
<b>I List of abbreviations.....</b>	<b>I.4</b>
<b>I 1 Executive summary of the benefit assessment .....</b>	<b>I.5</b>
<b>I 2 Research question.....</b>	<b>I.11</b>
<b>I 3 Information retrieval and study pool.....</b>	<b>I.13</b>
<b>I 4 Results on added benefit.....</b>	<b>I.19</b>
<b>I 5 Probability and extent of added benefit .....</b>	<b>I.20</b>
<b>I 6 References for English extract .....</b>	<b>I.21</b>

**I List of tables<sup>2</sup>**

	<b>Page</b>
Table 2: Research question of the benefit assessment of finerenone .....	I.5
Table 3: Finerenone – probability and extent of added benefit.....	I.10
Table 4: Research question of the benefit assessment of finerenone .....	I.11
Table 5: Finerenone – probability and extent of added benefit.....	I.20

---

<sup>2</sup> Table numbers start with “2” as numbering follows that of the full dossier assessment.

## I List of abbreviations

<b>Abbreviation</b>	<b>Meaning</b>
ACE	angiotensin-converting enzyme
ACT	appropriate comparator therapy
ARB	angiotensin receptor blocker
CKD	chronic kidney disease
eGFR	estimated glomerular filtration rate
G-BA	Gemeinsamer Bundesausschuss (Federal Joint Committee)
HbA1c	glycated haemoglobin
IPD	individual patient data
IQWiG	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care)
KDIGO	Kidney Disease: Improving Global Outcomes
NYHA	New York Heart Association
RCT	randomized controlled trial
SGB	Sozialgesetzbuch (Social Code Book)
SGLT2	sodium-glucose cotransporter 2
SPC	Summary of Product Characteristics
UACR	urine albumin creatinine ratio

## I 1 Executive summary of the benefit assessment

### Background

In accordance with § 35a Social Code Book (SGB) V, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the benefit of the drug finerenone. The assessment is based on a dossier compiled by the pharmaceutical company (hereinafter referred to as the “company”). The dossier was sent to IQWiG on 24 February 2023.

### Research question

The aim of this report is to assess the added benefit of finerenone compared to optimized standard therapy as an appropriate comparator therapy (ACT) in patients with stage 3 and 4 chronic kidney disease (CKD) with albuminuria in combination with type 2 diabetes mellitus.

The research question presented in Table 2 is derived from the ACT specified by the G-BA.

Table 2: Research question of the benefit assessment of finerenone

Therapeutic indication	ACT <sup>a</sup>
Adults with chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes mellitus	Optimized standard therapy for the treatment of chronic kidney disease and type 2 diabetes mellitus, taking into account the underlying disease(s) and common comorbidities (such as dyslipoproteinaemia, hypertension, anaemia) <sup>b</sup>
<p>a. Presented is the ACT specified by the G-BA.</p> <p>b. Comments of the G-BA:</p> <ul style="list-style-type: none"> <li>▫ It is assumed that, according to the current state of medical knowledge, treatment of CKD includes the use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor subtype 1 (AT1) antagonists, if they are an option and not contraindicated or intolerable. ACE inhibitors or AT1 antagonists are thus to be used (in the treatment situation of the add-on therapy) in both study arms.</li> <li>▫ Within the framework of the ACT, it is assumed that individualized treatment of the underlying disease, in particular type 2 diabetes mellitus, and any comorbidities that may be present, is carried out in accordance with the current state of medical knowledge, avoiding the use of nephrotoxic drugs in both treatment arms. There is a discrepancy between drugs for the treatment of CKD recommended in the guidelines and approved drugs.</li> <li>▫ Placebo or the unchanged continuation of an inadequate treatment of the underlying disease does not correspond to an ACT if there are still further options for treatment optimization.</li> <li>▫ For the target population to be treated, target values for comorbidities (such as diabetes mellitus, hypertension, dyslipoproteinaemia, anaemia) are to be defined before the start of the study, which the patients should reach before the start of the study or, if applicable, during a run-in phase and which they should maintain during the study by means of individualized treatment (e.g. dose adjustments). The target values should be based on the treatment standards of the corresponding diseases and, if applicable, take multiple comorbidities into account.</li> <li>▫ It is assumed that the goal of the patients in the planned therapeutic indication still is a slowdown of disease progression, so that renal replacement therapy in the form of dialysis or transplantation is not yet indicated for the patients.</li> </ul> <p>ACE: angiotensin-converting enzyme; AT1: angiotensin receptor subtype 1; G-BA: Federal Joint Committee</p>	



The company followed the G-BA's specification of the ACT.

In its dossier, the company also addresses the research question on adult patients with stage 1 and 2 CKD with albuminuria in combination with diabetes mellitus type 2. This research question is part of the benefit assessment A23-14 and this part of the dossier is assessed there.

The assessment is conducted by means of patient-relevant outcomes on the basis of the data presented by the company in the dossier. Randomized controlled trials (RCTs) with a minimum duration of 24 weeks are used for deriving the added benefit. This concurs with the company's inclusion criteria.

Hereinafter, the term CKD and renal insufficiency are used synonymously.

## Results

The check of completeness of the study pool did not reveal any relevant study for assessing the added benefit of finerenone in comparison with the ACT for the present research question. This deviates from the assessment of the company, whose information retrieval identified the RCTs FIDELIO-DKD and FIGARO-DKD. For each of these studies, it presented subpopulations as well as a prespecified meta-analysis based on individual patient data (IPD), which it used to assess the added benefit of finerenone.

The studies FIDELIO-DKD and FIGARO-DKD included by the company are not suitable for the assessment of the added benefit of finerenone versus the ACT because the ACT was not implemented. This is justified below.

### ***Evidence presented by the company – FIDELIO-DKD study***

The FIDELIO-DKD study is a placebo-controlled, double-blind, randomized parallel-group study on finerenone. Patients with type 2 diabetes mellitus according to the American Diabetes Association and CKD with a urine albumin creatinine ratio (UACR)  $\geq 30$  to  $< 300$  mg/g and an estimated glomerular filtration rate (eGFR) of  $\geq 25$  to  $< 60$  ml/min/1.73m<sup>2</sup> or a UACR of  $\geq 300$  mg/g and an eGFR of  $\geq 25$  to  $< 75$  ml/min/1.73m<sup>2</sup> were included. At least 4 weeks before screening, patients had to be treated with a maximum tolerated and stable dose of ACE inhibitors or angiotensin receptor blockers (ARB), which was ensured as part of treatment optimization during the run-in phase. Patients with known non-diabetic kidney disease or class II to IV symptomatic heart failure (according to the New York Heart Association [NYHA]) and reduced ejection fraction were excluded. Patients with uncontrolled arterial hypertension of  $\geq 160/100$  mmHg at the time of screening or glycated haemoglobin (HbA1c) levels of  $> 12\%$  were also excluded. Eplerenone, spironolactone, renin inhibitors and potassium-sparing diuretics were not allowed from 4 weeks before screening. A total of 5734 patients were included and assigned in a 1:1 ratio to treatment with finerenone (N = 2866) or to the placebo group (N = 2868). According to the study protocol, the study participants were to be treated

with an individually adapted therapy according to local guidelines and recommendations for CKD, type 2 diabetes mellitus and, if applicable, further comorbidities.

The primary outcome of the study was the composite outcome consisting of the components “renal insufficiency”, “persistent decrease of eGFR by  $\geq 40\%$ ” and “renal death”. Patient-relevant outcomes were recorded in the categories of mortality, morbidity, health-related quality of life and side effects.

### ***Evidence presented by the company – FIGARO-DKD study***

The FIGARO-DKD study is a placebo-controlled, double-blind, randomized parallel-group study on finerenone. Patients with type 2 diabetes mellitus according to the American Diabetes Association and CKD with a UACR of  $\geq 30$  to  $< 300$  mg/g and an eGFR of  $\geq 25$  to  $\leq 90$  ml/min/1.73 m<sup>2</sup> or a UACR of  $\geq 300$  mg/g and an eGFR of  $\geq 60$  ml/min/1.73 m<sup>2</sup> were included. At least 4 weeks before screening, patients had to be treated with a maximum tolerated and stable dose of ACE inhibitors or ARBs, which was ensured as part of treatment optimization during the run-in phase. Patients with known non-diabetic kidney disease or class II to IV symptomatic heart failure (according to the NYHA) and reduced ejection fraction were excluded. Patients with uncontrolled arterial hypertension of  $\geq 160/100$  mmHg at the time of screening or HbA1c levels of  $> 12\%$  were also excluded. Eplerenone, spironolactone, renin inhibitors and potassium-sparing diuretics were not allowed from 4 weeks before screening. A total of 7437 patients were included and assigned in a 1:1 ratio to treatment with finerenone (N = 3723) or to the placebo group (N = 3714). According to the study protocol, the study participants were to be treated with an individually adapted therapy according to local guidelines and recommendations for CKD, type 2 diabetes mellitus and, if applicable, further comorbidities.

The study’s primary outcome was the composite outcome of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or hospitalization for heart failure. Further patient-relevant outcomes were recorded in the categories of mortality, morbidity, health-related quality of life and side effects.

### ***Subpopulations of the studies FIDELIO-DKD and FIGARO-DKD presented by the company***

To answer the research question of the G-BA, the company formed subpopulations of the studies FIDELIO-DKD and FIGARO-DKD based on the diagnostic criteria of the guideline “Kidney Disease: Improving Global Outcomes” (KDIGO). The criterion used for stage 3 and 4 CKD is an eGFR  $< 60$  ml/min/1.73m<sup>2</sup>. This approach is generally appropriate. The company’s classification results in a subpopulation with 5242 patients (2622 in the intervention arm and 2620 in the comparator arm) from the FIDELIO-DKD study and a subpopulation of 2721 patients (1359 in the intervention arm and 1362 in the comparator arm) from the FIGARO-DKD study.

### ***ACT specified by the G-BA not implemented***

As ACT in the present therapeutic indication, the G-BA specified optimized standard therapy for the treatment of CKD and type 2 diabetes mellitus, taking into account the underlying disease(s) and common comorbidities (such as dyslipoproteinaemia, hypertension, anaemia).

In both studies, FIDELIO-DKD and FIGARO-DKD, patients were to receive individualized standard treatment according to the recommendations of the local guidelines. This applied to the treatment of CKD and type 2 diabetes mellitus and to the treatment of comorbidities such as e.g. hypertension. In both studies, there were no restrictions regarding treatment changes and dose adjustments of concomitant treatment after randomization. However, the studies FIDELIO-DKD and FIGARO-DKD included by the company are not suitable for the assessment of the added benefit versus the ACT for the present research question, as particularly the treatment of CKD and hypertension does not correspond to an optimized standard treatment. This is justified below.

#### *Treatment of CKD*

According to the ACT, CKD, type 2 diabetes mellitus and any comorbidities should be treated with an individualized treatment that corresponds to the current state of medical knowledge. In order to reduce cardiovascular events and CKD progression, patients with CKD and type 2 diabetes mellitus should be offered treatment with an SGLT2 inhibitor, e.g. dapagliflozin. The G-BA also identified a considerable added benefit for dapagliflozin for patients with CKD without symptomatic chronic heart failure as a comorbidity. The patients with an eGFR < 60 ml/min/1.73m<sup>2</sup> included in the studies FIDELIO-DKD and FIGARO-DKD largely correspond to the patients for whom the G-BA identified a considerable added benefit (adults with CKD without symptomatic chronic heart failure as a comorbidity). Sufficient implementation of the ACT in the studies FIDELIO-DKD and FIGARO-DKD therefore requires extensive use of dapagliflozin for the treatment of CKD. However, only a small proportion of patients received an SGLT2 inhibitor (4% to 6% at baseline, 6% to 13% newly started treatments during the course of the study). Thus, the ACT for the treatment of CKD was not implemented in the subpopulation relevant to the present benefit assessment.

#### *Treatment of arterial hypertension*

According to the notes of the G-BA, target values for the comorbidities should be defined and achieved before the start of the study and maintained during the course of the study by means of individualized treatment. In its study documents, the company follows the recommendation of the KDIGO guideline of 2012 with a target value of 130/80 mmHg with individual adjustment if necessary. However, according to the exclusion criteria, blood pressure values of up to 160/100 mmHg were allowed for patients to be included in the study. Moreover, treatment with aldosterone antagonists (eplerenone and spironolactone) and other potassium-sparing diuretics was not allowed from 4 weeks before screening and during

treatment with the study medication. Overall, there was inadequate blood pressure control at baseline. In the subpopulations presented, more than 25% of the patients had a systolic blood pressure of > 144 mmHg. The company provided information on blood pressure values during the course of the study only for the total populations of the studies. There was no relevant improvement in blood pressure values during the course of the study. Most importantly, the blood pressure remained consistently 2 to 3 mmHg higher in the comparator arm than in the intervention arm.

Overall, optimized treatment of arterial hypertension in the sense of the ACT was not guaranteed in the subpopulations of the studies FIDELIO-DKD and FIGARO-DKD presented by the company, especially in the comparator arms.

### *Conclusion*

For a large proportion of patients in the subpopulation of the studies FIDELIO-DKD and FIGARO-DKD relevant to the present benefit assessment, CKD was not treated with SGLT2 inhibitors, for which the G-BA determined a considerable added benefit (dapagliflozin) in this therapeutic indication and whose use is recommended by current guidelines. In addition, optimized treatment of arterial hypertension was not guaranteed, especially for patients in the comparator arms of the two studies. Several drugs for the treatment of oedema or of heart failure that might occur in the course were not available. In summary, the ACT of an optimized standard therapy was not implemented in the studies FIDELIO-DKD and FIGARO-DKD.

### **Results on added benefit**

As no suitable data are available for the benefit assessment of finerenone in patients with stage 3 and 4 CKD with albuminuria in combination with type 2 diabetes mellitus, there is no hint of an added benefit of finerenone compared with the ACT; an added benefit is therefore not proven.

### **Probability and extent of added benefit, patient groups with therapeutically important added benefit<sup>3</sup>**

Table 3 shows a summary of probability and extent of the added benefit of finerenone.

---

<sup>3</sup> On the basis of the scientific data analysed, IQWiG draws conclusions on the (added) benefit or harm of an intervention for each patient-relevant outcome. Depending on the number of studies analysed, the certainty of their results, and the direction and statistical significance of treatment effects, conclusions on the probability of (added) benefit or harm are graded into 4 categories: (1) "proof", (2) "indication", (3) "hint", or (4) none of the first 3 categories applies (i.e., no data available or conclusions 1 to 3 cannot be drawn from the available data). The extent of added benefit or harm is graded into 3 categories: (1) major, (2) considerable, (3) minor (in addition, 3 further categories may apply: non-quantifiable extent of added benefit, added benefit not proven, or less benefit). For further details see [1,2].

Table 3: Finerenone – probability and extent of added benefit

<b>Therapeutic indication</b>	<b>ACT<sup>a</sup></b>	<b>Probability and extent of added benefit</b>
Adults with CKD (stage 3 and 4 with albuminuria) associated with type 2 diabetes mellitus	Optimized standard therapy for the treatment of CKD and type 2 diabetes mellitus, taking into account the underlying disease(s) and common comorbidities (such as dyslipoproteinaemia, hypertension, anaemia)	Added benefit not proven
a. Presented is the ACT specified by the G-BA. ACT: appropriate comparator therapy; G-BA: Federal Joint Committee		

The G-BA decides on the added benefit.

## 1.2 Research question

The aim of this report is to assess the added benefit of finerenone compared to optimized standard therapy as an ACT in patients with stage 3 and 4 CKD with albuminuria in combination with type 2 diabetes mellitus.

The research question presented in Table 4 is derived from the ACT specified by the G-BA.

Table 4: Research question of the benefit assessment of finerenone

Therapeutic indication	ACT <sup>a</sup>
Adults with chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes mellitus	Optimized standard therapy for the treatment of chronic kidney disease and type 2 diabetes mellitus, taking into account the underlying disease(s) and common comorbidities (such as dyslipoproteinaemia, hypertension, anaemia) <sup>b</sup>
<p>a. Presented is the ACT specified by the G-BA.</p> <p>b. Comments of the G-BA:</p> <ul style="list-style-type: none"> <li>▫ It is assumed that, according to the current state of medical knowledge, treatment of CKD includes the use of ACE inhibitors or AT1 antagonists, if they are an option and not contraindicated or intolerable. ACE inhibitors or AT1 antagonists are thus to be used (in the treatment situation of the add-on therapy) in both study arms.</li> <li>▫ Within the framework of the ACT, it is assumed that individualized treatment of the underlying disease, in particular type 2 diabetes mellitus, and any comorbidities that may be present, is carried out in accordance with the current state of medical knowledge, avoiding the use of nephrotoxic drugs in both treatment arms. There is a discrepancy between drugs for the treatment of CKD recommended in the guidelines and approved drugs.</li> <li>▫ Placebo or the unchanged continuation of an inadequate treatment of the underlying disease does not correspond to an ACT if there are still further options for treatment optimization.</li> <li>▫ For the target population to be treated, target values for comorbidities (such as diabetes mellitus, hypertension, dyslipoproteinaemia, anaemia) are to be defined before the start of the study, which the patients should reach before the start of the study or, if applicable, during a run-in phase and which they should maintain during the study by means of individualized treatment (e.g. dose adjustments). The target values should be based on the treatment standards of the corresponding diseases and, if applicable, take multiple comorbidities into account.</li> <li>▫ It is assumed that the goal of the patients in the planned therapeutic indication still is a slowdown of disease progression, so that renal replacement therapy in the form of dialysis or transplantation is not yet indicated for the patients.</li> </ul> <p>ACE: angiotensin-converting enzyme; AT1: angiotensin receptor subtype 1; G-BA: Federal Joint Committee</p>	

The company followed the G-BA's specification of the ACT.

In its dossier, the company also addresses the research question on adult patients with stage 1 and 2 CKD with albuminuria in combination with diabetes mellitus type 2. This research question is part of the benefit assessment A23-14 [3] and this part of the dossier is assessed there.

The assessment is conducted by means of patient-relevant outcomes on the basis of the data presented by the company in the dossier. RCTs with a minimum duration of 24 weeks are used for deriving the added benefit. This concurs with the company's inclusion criteria.

Hereinafter, the term CKD and renal insufficiency are used synonymously.

### **I 3 Information retrieval and study pool**

The study pool of the assessment was compiled on the basis of the following information:

Sources of the company in the dossier:

- study lists on finerenone (status: 16 December 2022)
- bibliographical literature search on finerenone (last search on 16 December 2022)
- search in trial registries/trial results databases for studies on finerenone (last search on 16 December 2022)
- search on the G-BA website for finerenone (last search on 16 December 2022)

To check the completeness of the study pool:

- search in trial registries for studies on finerenone (last search on 13 March 2023); for search strategies, see I Appendix A of the full dossier assessment

The check did not identify any additional relevant study.

The check of completeness of the study pool did not reveal any relevant study for assessing the added benefit of finerenone in comparison with the ACT for the present research question. This deviates from the assessment of the company, whose information retrieval identified the RCTs FIDELIO-DKD [4,5] and FIGARO-DKD [6,7]. For each of these studies, it presented subpopulations as well as a prespecified meta-analysis based on IPD, which it used to assess the added benefit of finerenone.

The studies FIDELIO-DKD and FIGARO-DKD included by the company are not suitable for the assessment of the added benefit of finerenone versus the ACT because the ACT was not implemented. This is justified below. For this purpose, the studies and subpopulations considered by the company are first described. Thereafter, it will be explained why the studies are not suitable for assessing the added benefit of finerenone compared to the ACT. The study results are presented in I Appendix B and I Appendix C as supplementary information.

#### **Evidence provided by the company**

##### ***FIDELIO-DKD***

The FIDELIO-DKD study is a placebo-controlled, double-blind, randomized parallel-group study on finerenone. Patients with type 2 diabetes mellitus according to the American Diabetes Association and CKD with a UACR  $\geq 30$  to  $< 300$  mg/g and an eGFR of  $\geq 25$  to  $< 60$  ml/min/1.73m<sup>2</sup> or a UACR of  $\geq 300$  mg/g and an eGFR of  $\geq 25$  to  $< 75$  ml/min/1.73m<sup>2</sup> were included. At least 4 weeks before screening, patients had to be treated with a maximum tolerated and stable dose of ACE inhibitors or ARBs, which was ensured as part of treatment



optimization during the run-in phase. Patients had to have a serum potassium level of  $\leq 4.8$  mmol/L for screening. Patients with known non-diabetic kidney disease or class II to IV symptomatic heart failure (according to the NYHA) and reduced ejection fraction were excluded. Patients with uncontrolled arterial hypertension of  $\geq 160/100$  mmHg at the time of screening or HbA1c levels of  $> 12\%$  were also excluded. Eplerenone, spironolactone, renin inhibitors and potassium-sparing diuretics were also not allowed from 4 weeks before screening.

A total of 5734 patients were included and assigned in a 1:1 ratio to treatment with finerenone (N = 2866) or to the placebo group (N = 2868). Patients were stratified by region (North America vs. Latin America vs. Europe vs. Asia vs. other), UACR at the time of screening (30 to  $< 300$  mg/g [high albuminuria] vs.  $\geq 300$  mg/g [very high albuminuria]) and eGFR at the time of screening (25 to  $< 45$  ml/min/1.73m<sup>2</sup> vs. 45 to  $< 60$  ml/min/1.73m<sup>2</sup> vs.  $\geq 60$  ml/min/1.73m<sup>2</sup>).

Treatment with finerenone was administered in compliance with the approval in the FIDELIO-DKD study [8]. According to the study protocol, the study participants were to be treated with an individually adapted therapy according to local guidelines and recommendations for CKD, type 2 diabetes mellitus and, if applicable, further comorbidities. A detailed discussion on the implementation of the ACT can be found below.

The study was event-driven and was planned to end after 1068 events of the primary outcome. Patients who discontinued the study medication prematurely were followed up until the end of the study. Patients who were still on treatment with finerenone at the end of the study were followed up until 33 days after the end of the study.

The primary outcome of the study was the composite outcome consisting of the components “renal insufficiency”, “persistent decrease of eGFR by  $\geq 40\%$ ” and “renal death”. Patient-relevant outcomes were recorded in the categories of mortality, morbidity, health-related quality of life and side effects.

### **FIGARO-DKD**

The FIGARO-DKD study is a placebo-controlled, double-blind, randomized parallel-group study on finerenone. Patients with type 2 diabetes mellitus according to the American Diabetes Association and CKD with a UACR of  $\geq 30$  to  $< 300$  mg/g and an eGFR of  $\geq 25$  to  $\leq 90$  ml/min/1.73m<sup>2</sup> or a UACR of  $\geq 300$  mg/g and an eGFR of  $\geq 60$  ml/min/1.73m<sup>2</sup> were included. At least 4 weeks before screening, patients had to be treated with a maximum tolerated and stable dose of ACE inhibitors or ARBs, which was ensured as part of treatment optimization during the run-in phase. Patients had to have a serum potassium level of  $\leq 4.8$  mmol/L for screening. Patients with known non-diabetic kidney disease or class II to IV symptomatic heart failure (according to the NYHA) and reduced ejection fraction were excluded from participation in the study. Patients with uncontrolled arterial hypertension of  $\geq 160/100$

mmHg at the time of screening and HbA1c levels of > 12% were also excluded. Eplerenone, spironolactone, renin inhibitors and potassium-sparing diuretics were also not allowed from 4 weeks before screening.

A total of 7437 patients were included and assigned in a 1:1 ratio to treatment with finerenone (N = 3723) or to the placebo group (N = 3714). Patients were stratified by region (North America vs. Latin America vs. Europe vs. Asia vs. other), history of a cardiovascular disease (present vs. not present), UACR at the time of screening (30 to < 300 mg/g [high albuminuria] vs.  $\geq$  300 mg/g [very high albuminuria]) and eGFR at the time of screening (25 to < 45 ml/min/1.73m<sup>2</sup> vs. 45 to < 60 ml/min/1.73m<sup>2</sup> vs.  $\geq$  60 ml/min/1.73m<sup>2</sup>).

Finerenone was administered in compliance with the approval in the FIGARO-DKD study [8]. According to the study protocol, the study participants were to be treated with an individually adapted therapy according to local guidelines and recommendations for CKD, type 2 diabetes mellitus and, if applicable, further comorbidities. A detailed discussion on the implementation of the ACT can be found below.

The study was event-driven and was planned to end after 976 events of the primary outcome. Patients who discontinued the study medication prematurely were followed up until the end of the study. Patients who were still on treatment with finerenone at the end of the study were followed up until 33 days after the end of the study.

The study's primary outcome was the composite outcome of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or hospitalization for heart failure. Further patient-relevant outcomes were recorded in the categories of mortality, morbidity, health-related quality of life and side effects.

#### ***Subpopulations of the studies FIDELIO-DKD and FIGARO-DKD presented by the company***

To answer the research question of the G-BA, the company formed subpopulations of the studies FIDELIO-DKD and FIGARO-DKD based on the diagnostic criteria of the KDIGO guideline [9]. The criterion used for stage 3 and 4 CKD is an eGFR < 60 ml/min/1.73m<sup>2</sup>. This approach is appropriate. The company's classification results in a subpopulation with 5242 patients (2622 in the intervention arm and 2620 in the comparator arm) from the FIDELIO-DKD study and a subpopulation of 2721 patients (1359 in the intervention arm and 1362 in the comparator arm) from the FIGARO-DKD study.

It should be noted that the company used the eGFR at the time of screening instead of the eGFR at baseline to form the subpopulations. As a result, a total of approx. 8% of the patients were allocated to the therapeutic indication "stage 3 and 4 CKD " relevant to the present benefit assessment, although the eGFR at baseline was  $\geq$  60 ml/min/1.73m<sup>2</sup> (stage 2) (see Table 8 and Table 18 of the full dossier assessment). The company did not justify its approach.

In addition, according to the Summary of Product Characteristics (SPC), finerenone therapy should not be started in patients with a serum potassium level  $\geq 5$  mmol/L. At baseline, about 6% to 7% of the patients showed a serum potassium level above this benchmark. It is unclear whether treatment was initiated in these patients or whether the initiation of treatment was delayed. These two aspects have no consequence for the present benefit assessment, as they affect less than 20% of the relevant patients and the ACT was not implemented in the subpopulations presented by the company (see following section).

### **ACT specified by the G-BA not implemented**

As ACT in the present therapeutic indication, the G-BA specified optimized standard therapy for the treatment of CKD and type 2 diabetes mellitus, taking into account the underlying disease(s) and common comorbidities (such as dyslipoproteinaemia, hypertension, anaemia).

In both studies, FIDELIO-DKD and FIGARO-DKD, patients were to receive individualized standard treatment according to the recommendations of the local guidelines. This applied to the treatment of CKD and type 2 diabetes mellitus and to the treatment of comorbidities such as e.g. hypertension. Guideline-compliant treatment with ACE inhibitors or ARBs in the maximum tolerated dose  $\geq 4$  weeks before screening was an inclusion criterion. In both studies, there were no restrictions regarding treatment changes and dose adjustments of concomitant treatment after randomization. The data presented on concomitant treatment at baseline and during the course of the study are presented in Table 9, Table 10, Table 19 and Table 20 of the full dossier assessment. However, the studies FIDELIO-DKD and FIGARO-DKD included by the company are not suitable for the assessment of the added benefit versus the ACT for the present research question, as particularly the treatment of CKD and hypertension does not correspond to an optimized standard treatment. This is justified below.

### ***Treatment of CKD***

According to the ACT, CKD and type 2 diabetes mellitus taking into account any underlying disease(s) and common comorbidities should be treated with an optimized standard therapy that corresponds to the current state of medical knowledge. To reduce cardiovascular events and CKD progression, patients with CKD and type 2 diabetes mellitus should be offered treatment with an SGLT2 inhibitor according to recommendations of current guidelines [10-12]. The G-BA also identified a considerable added benefit for the SGLT2 inhibitor dapagliflozin for patients with CKD without symptomatic chronic heart failure as a comorbidity [13]. The subpopulation of the studies FIDELIO-DKD and FIGARO-DKD relevant for the present benefit assessment comprised a large proportion of these patients. It can therefore be assumed that these patients will benefit from the considerable added benefit of dapagliflozin for the treatment of CKD determined by the G-BA. Sufficient implementation of the ACT in the relevant subpopulations of the studies FIDELIO-DKD and FIGARO-DKD therefore requires an extensive use of dapagliflozin for the treatment of CKD. Although the use of SGLT2 inhibitors

was basically allowed in the FIDELIO-DKD study, only 4% and 6% of patients in the relevant subpopulations received an SGLT2 inhibitor at baseline. Treatment with SGLT2 inhibitors was also initiated in only a small proportion of patients during the course of the study (6% and 13% respectively, see Table 10 and Table 20 of the full benefit assessment). The company did not present subgroup analyses on the use of SGLT2 inhibitors at baseline (yes vs. no) pre-specified in the statistical analysis plan; an analysis of the potentially relevant subpopulation with SGLT2 inhibitor treatment at baseline is therefore not available for the benefit assessment. The importance of these subgroup analyses for the assessment of the treatment effect of finerenone also follows from other national benefit assessment procedures, in which finerenone is mainly seen as an add-on to an ongoing treatment with dapagliflozin [14,15]. However, these subgroup analyses can basically only address the research question of finerenone as an add-on therapy (finerenone plus SGLT2 inhibitors or GLP-1-receptor agonists vs. SGLT2 inhibitors or GLP-1-receptor agonists) and not the comparison between finerenone and SGLT2 inhibitors or GLP-1-receptor agonists. The company also seemed to consider this add-on question relevant and addressed it in its ongoing phase 2 study CONFIDENCE comparing finerenone + empagliflozin with monotherapy with empagliflozin or finerenone [16].

Overall, the ACT for the treatment of CKD was not implemented in the subpopulation relevant to the present benefit assessment.

### ***Treatment of arterial hypertension***

According to the notes of the G-BA, target values for the comorbidities should be defined and achieved before the start of the study and maintained during the course of the study by means of individualized treatment. The KDIGO practice guideline on the management of blood pressure in CKD of 2012 [17] recommends a blood pressure of 130/80 mmHg for patients with CKD and type 2 diabetes mellitus including albuminuria (UACR  $\geq$  30 mg/g). According to the updated KDIGO practice guideline of 2021, a systolic blood pressure of < 120 mmHg [18] is even recommended for these patients.

In its study documents, the company follows the recommendation of the KDIGO guideline of 2012 [17] and specifies a target value of 130/80 mmHg with individual adjustment if necessary. However, according to the exclusion criteria, blood pressure values of up to 160/100 mmHg were allowed for patients to be included in the study. Moreover, treatment with aldosterone antagonists (eplerenone and spironolactone) and other potassium-sparing diuretics was not allowed from 4 weeks before screening and during treatment with the study medication. This meant that several drugs for the treatment of arterial hypertension, but also of oedema and potentially occurring heart failure were not available for patients, especially in the comparator arm. Overall, there was inadequate blood pressure control at baseline. In the subpopulations presented, 25% of the patients had a systolic blood pressure of > 140 mmHg

at baseline (see Table 8 and Table 18 of the full dossier assessment). The company provided information on blood pressure values during the course of the study only for the total populations of the studies. There was no relevant improvement in blood pressure values during the course of the study. Notably, blood pressure in the comparator arm remained consistently 2 to 3 mmHg higher than in the intervention arm, potentially due to the blood pressure-lowering effect of finerenone in the intervention arm [6,19].

Overall, optimized treatment of arterial hypertension in the sense of the ACT was not guaranteed in the subpopulations of the studies FIDELIO-DKD and FIGARO-DKD presented by the company, especially in the comparator arms.

### **SGLT2 inhibitors and liraglutide for the treatment of type 2 diabetes mellitus**

The patients included in the studies FIGARO-DKD and FIDELIO-DKD all had type 2 diabetes mellitus in addition to CKD. According to current guidelines, patients with type 2 diabetes mellitus and concomitant cardiovascular disease should be offered SGLT2 inhibitors or liraglutide. However, the studies on which these recommendations are based (DECLARE-TIMI 58, EMPA-REG and LEADER) differ significantly from the relevant subpopulation of the FIGARO-DKD study, as the majority of the patients included there had an eGFR > 60 ml/min/1.73 m<sup>2</sup>. Therefore, there is only limited evidence for the treatment of type 2 diabetes mellitus with SGLT2 inhibitors for patients with an eGFR < 60 ml/min/1.73 m<sup>2</sup>. It should be noted, however, that according to the current recommendations for patients with CKD, an individual target value of the HbA1c in the reference range of 6.5% to 8.5% should be agreed, taking into account various factors, such as comorbidities [20,21]. In the subpopulations of the studies FIDELIO-DKD and FIGARO-DKD, almost 19% and 24% of the relevant subpopulation, respectively, had an HbA1c value above the recommended reference range. Adjustment of diabetes treatment during the course of the study was allowed. Nevertheless, the proportion of patients with HbA1c values above 8.5% in the total population hardly changed during the course of the study (data for the relevant subpopulation are not available).

### **Conclusion**

For a large proportion of patients in the subpopulation of the studies FIDELIO-DKD and FIGARO-DKD relevant to the present benefit assessment, CKD was not treated with SGLT2 inhibitors, for which the G-BA determined a considerable added benefit (dapagliflozin) in this therapeutic indication and whose use is recommended by current guidelines. In addition, optimized treatment of arterial hypertension was not guaranteed, especially for patients in the comparator arms of the two studies. Several drugs for the treatment of oedema or of heart failure potentially occurring in the course were not available. In summary, the ACT of an optimized standard therapy was not implemented in the studies FIDELIO-DKD and FIGARO-DKD.

#### **I 4 Results on added benefit**

No suitable data are available for the assessment of the added benefit of finerenone compared to the ACT in patients with stage 3 and 4 CKD with albuminuria in connection with type 2 diabetes mellitus. There was no hint of an added benefit of finerenone in comparison with the ACT; an added benefit is therefore not proven for these patients.

## I 5 Probability and extent of added benefit

Table 5 summarizes the result of the assessment of added benefit for finerenone in comparison with the ACT.

Table 5: Finerenone – probability and extent of added benefit

<b>Therapeutic indication</b>	<b>ACT<sup>a</sup></b>	<b>Probability and extent of added benefit</b>
Adults with CKD (stage 3 and 4 with albuminuria) associated with type 2 diabetes mellitus	Optimized standard therapy for the treatment of CKD and type 2 diabetes mellitus, taking into account the underlying disease(s) and common comorbidities (such as dyslipoproteinaemia, hypertension, anaemia)	Added benefit not proven
a. Presented is the ACT specified by the G-BA. ACT: appropriate comparator therapy; G-BA: Federal Joint Committee		

The assessment described above deviates from that of the company, which derived proof of considerable added benefit.

The G-BA decides on the added benefit.

## I 6 References for English extract

Please see full dossier assessment for full reference list.

The reference list contains citations provided by the company in which bibliographical information may be missing.

1. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Allgemeine Methoden; Version 6.1 [online]. 2022 [Accessed: 27.01.2022]. URL: <https://www.iqwig.de/methoden/allgemeine-methoden-v6-1.pdf>.
2. Skipka G, Wieseler B, Kaiser T et al. Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs. *Biom J* 2016; 58(1): 43-58. <https://dx.doi.org/10.1002/bimj.201300274>.
3. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Finerenon (Niereninsuffizienz, Stadium 1 und 2) - Nutzenbewertung gemäß § 35a SGB V. 2023: [Demnächst verfügbar unter <https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/927/#nutzenbewertung>].
4. Bakris GL, Agarwal R, Anker SD et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. *N Engl J Med* 2020; 383(23): 2219-2229. <https://dx.doi.org/10.1056/NEJMoa2025845>.
5. Bayer. CSR FIDELIO-DKD 2020: A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease. 2020.
6. Pitt B, Filippatos G, Agarwal R et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. *N Engl J Med* 2021; 385(24): 2252-2263. <https://dx.doi.org/10.1056/NEJMoa2110956>.
7. Bayer. A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care; study 17530; Clinical Study Report [unpublished]. 2021.
8. Bayer. Kerendia 10 mg/20 mg Filmtabletten [online]. 2023 [Accessed: 14.04.2023]. URL: <https://www.fachinfo.de>.
9. International Society of Nephrology. KDIGO 2012; Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease; Kidney International Supplements [online]. 2013 [Accessed: 09.05.2023]. URL: [https://kdigo.org/wp-content/uploads/2017/02/KDIGO\\_2012\\_CKD\\_GL.pdf](https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf).



10. Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022; Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney Int* 2022; 102(5S): S1-S127. <https://dx.doi.org/10.1016/j.kint.2022.06.008>.
11. ElSayed NA, Aleppo G, Aroda VR et al. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. *Diabetes Care* 2023; 46(Suppl 1): S191-S202. <https://dx.doi.org/10.2337/dc23-S011>.
12. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management: NICE guideline [online]. 2022 [Accessed: 18.04.2023]. URL: <https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-pdf-1837338615493>.
13. Gemeinsamer Bundesausschuss. Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie: Anlage XII – Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V); Dapagliflozin (Neues Anwendungsgebiet: Chronische Niereninsuffizienz) [online]. 2022 [Accessed: 12.04.2023]. URL: [https://www.g-ba.de/downloads/39-261-5282/2022-02-17\\_AM-RL-XII\\_Dapagliflozin\\_D-713\\_BAnz.pdf](https://www.g-ba.de/downloads/39-261-5282/2022-02-17_AM-RL-XII_Dapagliflozin_D-713_BAnz.pdf).
14. Canadian's Drug and Health Technology Agency. Finerenone (Kerendia); CADTH Reimbursement Recommendation; *Canadian Journal of Health Technologies* [online]. 2023 [Accessed: 02.05.2023]. URL: <https://www.cadth.ca/sites/default/files/DRR/2023/SR0737REC-Kerendia.pdf>.
15. National Institute for Health and Care Excellence. Finerenone for treating chronic kidney disease in type 2 diabetes; Technology appraisal guidance [online]. 2023 [Accessed: 27.04.2023]. URL: <https://www.nice.org.uk/guidance/ta877/resources/finerenone-for-treating-chronic-kidney-disease-in-type-2-diabetes-pdf-82613678191045>.
16. Bayer. A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE) [online]. 2023 [Accessed: 14.04.2023]. URL: <https://clinicaltrials.gov/ct2/show/NCT05254002>.
17. International Society of Nephrology. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease; *Kidney International Supplements* [online]. 2012 [Accessed: 04.01.2023]. URL: <https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Blood-Pressure-Guideline-English.pdf>.
18. International Society of Nephrology. KDIGO 2021; Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease; Supplement to *Kidney International* [online]. 2021 [Accessed: 18.04.2023]. URL: <https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2021-BP-GL.pdf>.

19. Ruilope LM, Agarwal R, Anker SD et al. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. *Hypertension* 2022; 79(12): 2685-2695. <https://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19744>.

20. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin. Versorgung von Patienten mit chronischer nicht-dialysepflichtiger Nierenerkrankung in der Hausarztpraxis; S3-Leitlinie [online]. 2019 [Accessed: 18.04.2023]. URL: [https://www.degam.de/files/Inhalte/Leitlinien-Inhalte/Dokumente/DEGAM-S3-Leitlinien/053-048\\_Versorgung%20von%20Patienten%20mit%20nicht-dialysepflichtiger%20Niereninsuffizienz%20in%20der%20Hausarztpraxis/oeffentlich/053-048I\\_Versorgung%20von%20Patienten%20mit%20nicht-dialysepflichtiger%20Niereninsuffizienz%20in%20der%20Hausarztpraxis\\_redakt\\_29-01-2021.pdf](https://www.degam.de/files/Inhalte/Leitlinien-Inhalte/Dokumente/DEGAM-S3-Leitlinien/053-048_Versorgung%20von%20Patienten%20mit%20nicht-dialysepflichtiger%20Niereninsuffizienz%20in%20der%20Hausarztpraxis/oeffentlich/053-048I_Versorgung%20von%20Patienten%20mit%20nicht-dialysepflichtiger%20Niereninsuffizienz%20in%20der%20Hausarztpraxis_redakt_29-01-2021.pdf).

21. Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie; Typ-2-Diabetes; Teilpublikation der Langfassung; 2. Auflage, Version 1 [online]. 2021 [Accessed: 18.04.2023]. URL: <https://www.leitlinien.de/themen/diabetes/pdf/diabetes-2aufl-vers1.pdf>.

*The full report (German version) is published under*  
<https://www.iqwig.de/en/projects/a23-15.html>.